Registering patients undergoing heated chemotherapy for peritoneal cancers
Register With Data From Patients With the Diagnosis of a Peritoneal Surface Malignancy, for Which Cytoreductive Surgery and Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) is Performed
This study is collecting information from patients with certain abdominal cancers who are having surgery followed by heated chemotherapy to see if it helps them live longer and feel better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 125 (estimated) |
| Sex | All |
| Sponsor | Universitaire Ziekenhuizen KU Leuven Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Leuven, Flemish Brabant) |
| Trial ID | NCT01617382 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect follow-up data from patients diagnosed with peritoneal surface malignancies who will undergo cytoreductive surgery followed by hyperthermic intra-peritoneal chemotherapy (HIPEC). The procedure involves removing visible tumors from the abdominal cavity and rinsing it with heated chemotherapy to eliminate any remaining cancer cells. The goal is to improve patient survival and prognosis by ensuring thorough treatment of peritoneal carcinomatosis, pseudomyxoma peritonei, and peritoneal mesothelioma.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with peritoneal carcinomatosis of colorectal origin, pseudomyxoma peritonei, or peritoneal mesothelioma who are scheduled for cytoreductive surgery and HIPEC.
Not a fit: Patients with peritoneal malignancies not eligible for cytoreductive surgery or HIPEC may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly enhance survival rates for patients with peritoneal surface malignancies.
How similar studies have performed: Other studies have shown promising results with HIPEC in similar patient populations, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with peritoneal carcinomatosis of colorectal origin, patients with pseudomyxoma peritonei (type DPAM or PMCA) and patients with peritoneal mesothelioma who are planned to undergo cytoreductive surgery and HIPEC because of a peritoneal surface malignancy
Where this trial is running
Leuven, Flemish Brabant
- University Clinics Gasthuisberg — Leuven, Flemish Brabant, Belgium (Recruiting)
Study contacts
- Principal investigator: André JL D'Hoore, PhD — University Clinics Gasthuisberg Department of Abdominal Surgery
- Study coordinator: Isabelle B Terrasson
- Email: isabelle.terrasson@uzleuven.be
- Phone: +32 16 340837
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.